
0:00
1:02:42
- GLP1 drugs work but they likely need lifestyle modifications
 
- No convincing evidence GLP1 cause thyroid cancer in humans BUT contraindication if family history exist
 
- Stopping therapy usually results in weight gain
 
- Insurance coverage for weight loss is limited and variable
 
- Semaglutide for type 2 diabetes max dose is 2.0 mg weekly Semaglutide for weight loss has a goal dose of 2.4 mg weekly
 - Diagnose steatotic liver disease with imaging and 1 metabolic risk factor (or biopsy)
 
- After diagnosis check FIB-4:
- Low risk, continue to monitor with FIB-4 every 2-3yrs
 - Intermediate risk, order VCTE and consider referral if >F1
 - High risk order a VCTE and referral (20% end with SLD)
 
 
- 2 FDA approved medications for liver fibrosis are not cheap, expect insurance push back
 
Flere episoder fra "Questioning Medicine"



Gå ikke glip af nogen episoder af “Questioning Medicine” - abonnér på podcasten med gratisapp GetPodcast.







